Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Heron Therapeutics (HRTX) Gross Margin (2016 - 2025)

Heron Therapeutics (HRTX) has disclosed Gross Margin for 10 consecutive years, with 72.61% as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Gross Margin fell 231.0% year-over-year to 72.61%, compared with a TTM value of 73.31% through Dec 2025, up 9.0%, and an annual FY2025 reading of 73.31%, up 9.0% over the prior year.
  • Gross Margin was 72.61% for Q4 2025 at Heron Therapeutics, up from 68.82% in the prior quarter.
  • Across five years, Gross Margin topped out at 78.26% in Q1 2025 and bottomed at 67.73% in Q3 2021.
  • Average Gross Margin over 5 years is 46.61%, with a median of 56.87% recorded in 2022.
  • The sharpest move saw Gross Margin plummeted -13181bps in 2021, then skyrocketed 11231bps in 2022.
  • Year by year, Gross Margin stood at 18.55% in 2021, then soared by 320bps to 40.81% in 2022, then surged by 74bps to 71.12% in 2023, then rose by 5bps to 74.92% in 2024, then fell by -3bps to 72.61% in 2025.
  • Business Quant data shows Gross Margin for HRTX at 72.61% in Q4 2025, 68.82% in Q3 2025, and 73.5% in Q2 2025.